Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines. 

duración terapia de doble antiagregación plaquetaria

Clinical studies that investigated single antiplatelet therapy versus DAPT until November 2020 were analyzed and divided according to DAPT duration. 

Researchers calculated risk ratios of major or life‐threatening bleeding, stroke, and all‐cause mortality. 

Studies using oral anticoagulants and antiplatelet therapy concomitantly, such as those on atrial fibrillation, were excluded. 

It included four randomized controlled trials, 2 propensity‐score matched studies, and 1 observational study, with a total 2498 patients.

1249 received monotherapy, 485 received DAPT for 3 months and 764 received DAPT for 6 months. All these studies used aspirin as monotherapy. 


Read also: CT and Angiography Agreement in Patients from the ISCHEMIA Trial.


The analysis showed that aspirin monotherapy significantly reduced the risk of life-threatening bleeding vs. 3-month DAPT (RR=2.13, p=0.016) and 6-month DAPT (RR=2.54, p=0.007).

There were no differences when comparing 3-month vs 6-month DAPT.

Stroke and mortality rates were similar across groups. 


Read also: Cerebral Protection Devices during TAVR in the Daily Practice.


Clinical guidelines indicating post TAVR DAPT await updating after several studies, and more recently, a meta-analysis with consistent results in favor of monotherapy. 

Conclusion

Aspirin monotherapy after TAVR reduced the risk of bleeding and did not increase stroke or mortality rate vs. 3- and 6-month DAPT. 

JAHA-120-019490free

Original Title: Duration of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement: Systematic Review and Network Meta-Analysis.

Reference: Toshiki Kuno et al. J Am Heart Assoc. 2021;10:e019490.  DOI: 10.1161/JAHA.120.019490.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....